Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417

Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium ® and Detalliptinium ®, two ellipticine derivati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochemical pharmacology 1989-07, Vol.38 (13), p.2077-2086
Hauptverfasser: Multon, Eric, Riou, Jean-François, LeFevre, Dominique, Ahomadegbe, Jean-Charles, Riou, Guy
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2086
container_issue 13
container_start_page 2077
container_title Biochemical pharmacology
container_volume 38
creator Multon, Eric
Riou, Jean-François
LeFevre, Dominique
Ahomadegbe, Jean-Charles
Riou, Guy
description Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium ® and Detalliptinium ®, two ellipticine derivatives clinically used for their antitumoral properties against breast cancer, exhibit the highest in vitro activity on Topo II DNA cleavage reaction and decatenation among a series of 14 ellipticine derivatives. The in vitro cleavage site specificity in pBR 322 plasmid DNA and in a human c-myc gene inserted in a lambda phage DNA is identical for both ellipticines, but different from m-AMSA, another Topo II related antitumoral agent. Recently, it has been shown that the ellipticine derivative Celiptium ® presents a strong cytotoxic activity in vitro on different human tumors including small cell lung carcinoma (SCLC). However, the studies that involved Topo II as a target for ellipticine derivatives have been performed only by using animal tumor cell lines. Therefore we have studied the in vivo DNA cleavage activity of Celiptium ® and Detalliptinium ® on a human SCLC cell line, NCI N417, comparatively to that obtained with m-AMSA. The respective IC 50 on cell growth are 9, 8 and 1 μM for Celiptium ®, Detalliptinium ® and m-AMSA, respectively. Using the alkaline elution technique, we have observed that Celiptium ® and Detalliptinium ® exhibit a weak cleavage activity on genomic DNA from whole cells. The ellipticines are about 50 times less potent than m-AMSA in inducing DNA strand breaks. Analysis of in vivo c-myc gene cleavage by Southern blot hybridization also demonstrates a lack of activity of the ellipticine derivatives as no gene cleavage could be detected up to 50μM of the drug. With m-AMSA, c-myc gene cleavage is detected at a concentration of 0.2μM, which indicates that this methodology is less sensitive in detecting DNA strand breaks than is the alkaline elution. Further studies of the drug effect on isolated nuclei by alkaline elution also show that the DNA cleavage activity of Celiptium ® and Detalliptinium ® is increased when compared to whole cells. Our data indicate that these two drugs have a weaker cytotoxic effect than m-AMSA on NCI N417 cell line, due to a limited access to the cell nucleus rather than to a lack of activity on Topo II as assessed by in vitro and isolated nuclei experiments.
doi_str_mv 10.1016/0006-2952(89)90060-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79046978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0006295289900609</els_id><sourcerecordid>79046978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-ff4a834363b18774fda7ad5f5ec04a7f9dfe3465cd6bf0c4dacec64a1f1f3e633</originalsourceid><addsrcrecordid>eNp9kE1vEzEQhi0EKmnhH4DkA0JwWLBjrz8ulapSIFJVLuVsTewxNdqPYO9Gyr_HS6IcOdnj95nR-CHkDWefOOPqM2NMNWvbrj8Y-9HWgjX2GVlxo0V9VuY5WZ2Rl-SylN9LaRS_IBfrVkpuxIqkx3E3pjL2mKEg3WyaHkOCCQP98nBDfYewh19IwU9pn6YDTUOYfU23B4pdl3ZT8mnAQseBTk9In-Ye6m3ux0x9BWhXU_oguX5FXkToCr4-nVfk59e7x9vvzf2Pb5vbm_vGC6OmJkYJRkihxLb-RMsYQENoY4ueSdDRhohCqtYHtY3MywAevZLAI48ClRBX5P1x7i6Pf2Ysk-tTWVaBAce5OG2ZVFabCsoj6PNYSsbodjn1kA-OM7cYdosvt-hzxrp_hp2tbW9P8-dtdXVuOimt-btTDsVDFzMMPpUzplptlWYVuz5iWF3sE2ZXfMKhqk0Z_eTCmP6_x1_U4Zgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79046978</pqid></control><display><type>article</type><title>Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Multon, Eric ; Riou, Jean-François ; LeFevre, Dominique ; Ahomadegbe, Jean-Charles ; Riou, Guy</creator><creatorcontrib>Multon, Eric ; Riou, Jean-François ; LeFevre, Dominique ; Ahomadegbe, Jean-Charles ; Riou, Guy</creatorcontrib><description>Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium ® and Detalliptinium ®, two ellipticine derivatives clinically used for their antitumoral properties against breast cancer, exhibit the highest in vitro activity on Topo II DNA cleavage reaction and decatenation among a series of 14 ellipticine derivatives. The in vitro cleavage site specificity in pBR 322 plasmid DNA and in a human c-myc gene inserted in a lambda phage DNA is identical for both ellipticines, but different from m-AMSA, another Topo II related antitumoral agent. Recently, it has been shown that the ellipticine derivative Celiptium ® presents a strong cytotoxic activity in vitro on different human tumors including small cell lung carcinoma (SCLC). However, the studies that involved Topo II as a target for ellipticine derivatives have been performed only by using animal tumor cell lines. Therefore we have studied the in vivo DNA cleavage activity of Celiptium ® and Detalliptinium ® on a human SCLC cell line, NCI N417, comparatively to that obtained with m-AMSA. The respective IC 50 on cell growth are 9, 8 and 1 μM for Celiptium ®, Detalliptinium ® and m-AMSA, respectively. Using the alkaline elution technique, we have observed that Celiptium ® and Detalliptinium ® exhibit a weak cleavage activity on genomic DNA from whole cells. The ellipticines are about 50 times less potent than m-AMSA in inducing DNA strand breaks. Analysis of in vivo c-myc gene cleavage by Southern blot hybridization also demonstrates a lack of activity of the ellipticine derivatives as no gene cleavage could be detected up to 50μM of the drug. With m-AMSA, c-myc gene cleavage is detected at a concentration of 0.2μM, which indicates that this methodology is less sensitive in detecting DNA strand breaks than is the alkaline elution. Further studies of the drug effect on isolated nuclei by alkaline elution also show that the DNA cleavage activity of Celiptium ® and Detalliptinium ® is increased when compared to whole cells. Our data indicate that these two drugs have a weaker cytotoxic effect than m-AMSA on NCI N417 cell line, due to a limited access to the cell nucleus rather than to a lack of activity on Topo II as assessed by in vitro and isolated nuclei experiments.</description><identifier>ISSN: 0006-2952</identifier><identifier>EISSN: 1873-2968</identifier><identifier>DOI: 10.1016/0006-2952(89)90060-9</identifier><identifier>PMID: 2544183</identifier><identifier>CODEN: BCPCA6</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Alkaloids - pharmacology ; Amsacrine - pharmacology ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; Carcinoma, Small Cell ; Cell Division - drug effects ; Cell Line ; DNA - drug effects ; DNA Damage ; DNA Topoisomerases, Type II - metabolism ; Ellipticines - pharmacology ; General aspects ; Humans ; Lung Neoplasms ; Medical sciences ; Pharmacology. Drug treatments ; Tumor Cells, Cultured - drug effects ; Tumor Cells, Cultured - enzymology</subject><ispartof>Biochemical pharmacology, 1989-07, Vol.38 (13), p.2077-2086</ispartof><rights>1989</rights><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-ff4a834363b18774fda7ad5f5ec04a7f9dfe3465cd6bf0c4dacec64a1f1f3e633</citedby><cites>FETCH-LOGICAL-c386t-ff4a834363b18774fda7ad5f5ec04a7f9dfe3465cd6bf0c4dacec64a1f1f3e633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0006295289900609$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=6579670$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2544183$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Multon, Eric</creatorcontrib><creatorcontrib>Riou, Jean-François</creatorcontrib><creatorcontrib>LeFevre, Dominique</creatorcontrib><creatorcontrib>Ahomadegbe, Jean-Charles</creatorcontrib><creatorcontrib>Riou, Guy</creatorcontrib><title>Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417</title><title>Biochemical pharmacology</title><addtitle>Biochem Pharmacol</addtitle><description>Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium ® and Detalliptinium ®, two ellipticine derivatives clinically used for their antitumoral properties against breast cancer, exhibit the highest in vitro activity on Topo II DNA cleavage reaction and decatenation among a series of 14 ellipticine derivatives. The in vitro cleavage site specificity in pBR 322 plasmid DNA and in a human c-myc gene inserted in a lambda phage DNA is identical for both ellipticines, but different from m-AMSA, another Topo II related antitumoral agent. Recently, it has been shown that the ellipticine derivative Celiptium ® presents a strong cytotoxic activity in vitro on different human tumors including small cell lung carcinoma (SCLC). However, the studies that involved Topo II as a target for ellipticine derivatives have been performed only by using animal tumor cell lines. Therefore we have studied the in vivo DNA cleavage activity of Celiptium ® and Detalliptinium ® on a human SCLC cell line, NCI N417, comparatively to that obtained with m-AMSA. The respective IC 50 on cell growth are 9, 8 and 1 μM for Celiptium ®, Detalliptinium ® and m-AMSA, respectively. Using the alkaline elution technique, we have observed that Celiptium ® and Detalliptinium ® exhibit a weak cleavage activity on genomic DNA from whole cells. The ellipticines are about 50 times less potent than m-AMSA in inducing DNA strand breaks. Analysis of in vivo c-myc gene cleavage by Southern blot hybridization also demonstrates a lack of activity of the ellipticine derivatives as no gene cleavage could be detected up to 50μM of the drug. With m-AMSA, c-myc gene cleavage is detected at a concentration of 0.2μM, which indicates that this methodology is less sensitive in detecting DNA strand breaks than is the alkaline elution. Further studies of the drug effect on isolated nuclei by alkaline elution also show that the DNA cleavage activity of Celiptium ® and Detalliptinium ® is increased when compared to whole cells. Our data indicate that these two drugs have a weaker cytotoxic effect than m-AMSA on NCI N417 cell line, due to a limited access to the cell nucleus rather than to a lack of activity on Topo II as assessed by in vitro and isolated nuclei experiments.</description><subject>Alkaloids - pharmacology</subject><subject>Amsacrine - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Small Cell</subject><subject>Cell Division - drug effects</subject><subject>Cell Line</subject><subject>DNA - drug effects</subject><subject>DNA Damage</subject><subject>DNA Topoisomerases, Type II - metabolism</subject><subject>Ellipticines - pharmacology</subject><subject>General aspects</subject><subject>Humans</subject><subject>Lung Neoplasms</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumor Cells, Cultured - drug effects</subject><subject>Tumor Cells, Cultured - enzymology</subject><issn>0006-2952</issn><issn>1873-2968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1vEzEQhi0EKmnhH4DkA0JwWLBjrz8ulapSIFJVLuVsTewxNdqPYO9Gyr_HS6IcOdnj95nR-CHkDWefOOPqM2NMNWvbrj8Y-9HWgjX2GVlxo0V9VuY5WZ2Rl-SylN9LaRS_IBfrVkpuxIqkx3E3pjL2mKEg3WyaHkOCCQP98nBDfYewh19IwU9pn6YDTUOYfU23B4pdl3ZT8mnAQseBTk9In-Ye6m3ux0x9BWhXU_oguX5FXkToCr4-nVfk59e7x9vvzf2Pb5vbm_vGC6OmJkYJRkihxLb-RMsYQENoY4ueSdDRhohCqtYHtY3MywAevZLAI48ClRBX5P1x7i6Pf2Ysk-tTWVaBAce5OG2ZVFabCsoj6PNYSsbodjn1kA-OM7cYdosvt-hzxrp_hp2tbW9P8-dtdXVuOimt-btTDsVDFzMMPpUzplptlWYVuz5iWF3sE2ZXfMKhqk0Z_eTCmP6_x1_U4Zgg</recordid><startdate>19890701</startdate><enddate>19890701</enddate><creator>Multon, Eric</creator><creator>Riou, Jean-François</creator><creator>LeFevre, Dominique</creator><creator>Ahomadegbe, Jean-Charles</creator><creator>Riou, Guy</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19890701</creationdate><title>Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417</title><author>Multon, Eric ; Riou, Jean-François ; LeFevre, Dominique ; Ahomadegbe, Jean-Charles ; Riou, Guy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-ff4a834363b18774fda7ad5f5ec04a7f9dfe3465cd6bf0c4dacec64a1f1f3e633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Alkaloids - pharmacology</topic><topic>Amsacrine - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Small Cell</topic><topic>Cell Division - drug effects</topic><topic>Cell Line</topic><topic>DNA - drug effects</topic><topic>DNA Damage</topic><topic>DNA Topoisomerases, Type II - metabolism</topic><topic>Ellipticines - pharmacology</topic><topic>General aspects</topic><topic>Humans</topic><topic>Lung Neoplasms</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumor Cells, Cultured - drug effects</topic><topic>Tumor Cells, Cultured - enzymology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Multon, Eric</creatorcontrib><creatorcontrib>Riou, Jean-François</creatorcontrib><creatorcontrib>LeFevre, Dominique</creatorcontrib><creatorcontrib>Ahomadegbe, Jean-Charles</creatorcontrib><creatorcontrib>Riou, Guy</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Multon, Eric</au><au>Riou, Jean-François</au><au>LeFevre, Dominique</au><au>Ahomadegbe, Jean-Charles</au><au>Riou, Guy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417</atitle><jtitle>Biochemical pharmacology</jtitle><addtitle>Biochem Pharmacol</addtitle><date>1989-07-01</date><risdate>1989</risdate><volume>38</volume><issue>13</issue><spage>2077</spage><epage>2086</epage><pages>2077-2086</pages><issn>0006-2952</issn><eissn>1873-2968</eissn><coden>BCPCA6</coden><abstract>Ellipticine derivatives have been shown to induce DNA strand breaks by trapping DNA-topoisomerase II (Topo II) in an intermediary covalent complex between Topo II and DNA which could be related to their cytotoxic effects. We report here that Celiptium ® and Detalliptinium ®, two ellipticine derivatives clinically used for their antitumoral properties against breast cancer, exhibit the highest in vitro activity on Topo II DNA cleavage reaction and decatenation among a series of 14 ellipticine derivatives. The in vitro cleavage site specificity in pBR 322 plasmid DNA and in a human c-myc gene inserted in a lambda phage DNA is identical for both ellipticines, but different from m-AMSA, another Topo II related antitumoral agent. Recently, it has been shown that the ellipticine derivative Celiptium ® presents a strong cytotoxic activity in vitro on different human tumors including small cell lung carcinoma (SCLC). However, the studies that involved Topo II as a target for ellipticine derivatives have been performed only by using animal tumor cell lines. Therefore we have studied the in vivo DNA cleavage activity of Celiptium ® and Detalliptinium ® on a human SCLC cell line, NCI N417, comparatively to that obtained with m-AMSA. The respective IC 50 on cell growth are 9, 8 and 1 μM for Celiptium ®, Detalliptinium ® and m-AMSA, respectively. Using the alkaline elution technique, we have observed that Celiptium ® and Detalliptinium ® exhibit a weak cleavage activity on genomic DNA from whole cells. The ellipticines are about 50 times less potent than m-AMSA in inducing DNA strand breaks. Analysis of in vivo c-myc gene cleavage by Southern blot hybridization also demonstrates a lack of activity of the ellipticine derivatives as no gene cleavage could be detected up to 50μM of the drug. With m-AMSA, c-myc gene cleavage is detected at a concentration of 0.2μM, which indicates that this methodology is less sensitive in detecting DNA strand breaks than is the alkaline elution. Further studies of the drug effect on isolated nuclei by alkaline elution also show that the DNA cleavage activity of Celiptium ® and Detalliptinium ® is increased when compared to whole cells. Our data indicate that these two drugs have a weaker cytotoxic effect than m-AMSA on NCI N417 cell line, due to a limited access to the cell nucleus rather than to a lack of activity on Topo II as assessed by in vitro and isolated nuclei experiments.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>2544183</pmid><doi>10.1016/0006-2952(89)90060-9</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-2952
ispartof Biochemical pharmacology, 1989-07, Vol.38 (13), p.2077-2086
issn 0006-2952
1873-2968
language eng
recordid cdi_proquest_miscellaneous_79046978
source MEDLINE; Elsevier ScienceDirect Journals
subjects Alkaloids - pharmacology
Amsacrine - pharmacology
Antineoplastic agents
Antineoplastic Agents - pharmacology
Biological and medical sciences
Carcinoma, Small Cell
Cell Division - drug effects
Cell Line
DNA - drug effects
DNA Damage
DNA Topoisomerases, Type II - metabolism
Ellipticines - pharmacology
General aspects
Humans
Lung Neoplasms
Medical sciences
Pharmacology. Drug treatments
Tumor Cells, Cultured - drug effects
Tumor Cells, Cultured - enzymology
title Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A27%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Topoisomerase%20II-mediated%20DNA%20cleavage%20activity%20induced%20by%20ellipticines%20on%20the%20human%20tumor%20cell%20line%20N417&rft.jtitle=Biochemical%20pharmacology&rft.au=Multon,%20Eric&rft.date=1989-07-01&rft.volume=38&rft.issue=13&rft.spage=2077&rft.epage=2086&rft.pages=2077-2086&rft.issn=0006-2952&rft.eissn=1873-2968&rft.coden=BCPCA6&rft_id=info:doi/10.1016/0006-2952(89)90060-9&rft_dat=%3Cproquest_cross%3E79046978%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79046978&rft_id=info:pmid/2544183&rft_els_id=0006295289900609&rfr_iscdi=true